GLP-1 weight loss drugs containing tirzepatide (Mounjaro, Zepbound) can reduce heart-related health risks for people with ...

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 ...

If you could inject yourself with a substance that purports to make you tanner, fitter, and healthier, would you? Many people are saying "yes." Online, social media influencers tout vials of ...

Meta begins laying off hundreds of employees across five divisions Miley Cyrus's revisited 'loss' as Billy Ray skips Hannah Montana premiere US moves airborne troops, Marines as Iran rejects ceasefire ...

Researchers boosted levels of a heart-healing hormone in mice and pigs with a single injection of a new, experimental form of self-amplifying RNA that prolonged hormone synthesis for many weeks. When ...

The Kroger Family of Pharmacies honor manufacturer-sponsored programs, including Lilly's KwikPen Self-Pay Savings Card for Zepbound®, according to each program's eligibility requirements and terms and ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device. Lilly says the new pen expands patient choice, ...

Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen ...

About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...